Board of Directors

Michael Goldberg, M.B.A.

Mr. Goldberg is currently a partner and director at Bain & Company, based in its Los Angeles office.

He previously held senior positions at Deloitte Consulting and Hughes Aircraft. Mr. Goldberg is a management and strategy consultant whose expertise lies in helping companies develop and implement competitive and sustainable growth strategies, as well as dramatically improving operational performance. Throughout his career, Mr. Goldberg has led significant consulting efforts in the areas of corporate growth and new market development, competitive analysis, cost reduction, asset efficiency, mergers and acquisitions, and information technology strategy, specializing in highly regulated industries, with a particular focus in aerospace and defense.

Mr. Goldberg holds an M.B.A. from the Anderson School of Business at the University of California at Los Angeles, and graduated phi beta kappa with a B.A. in economics from Occidental College. He also served as a trustee on the Occidental College Board of Trustees and chaired Occidental College's alumni fund. He currently serves as a trustee for the La Cañada Educational Foundation endowment.

Stephanie Hsieh, J.D., M.B.A.
President and CEO

Ms. Hsieh has a proven track record of setting and executing on value-building corporate strategies, particularly strategic patent portfolios.

Most recently, she held a senior position at Impax Laboratories, Inc., working with both the generic and specialty pharma divisions, leading cross-functional teams on crafting and executing on business and product strategies, including negotiating key marketing, licensing and development agreements with several major pharmaceutical companies.

Over her career she has helped devise strategies for the protection and lifecycle management of branded products, consulted to life science companies and entrepreneurs on business and patent strategies, as well as managed and prosecuted patent portfolios.
Ms. Hsieh received her M.B.A. from Stanford University and J.D. from Columbia University where she was a Harlan Fiske Stone Scholar. She received her B.A. in biological chemistry from Wellesley College where she graduated magna cum laude and phi beta kappa.

Robert Kramer, Ph.D.

Dr. Kramer is an established pharmaceutical research executive with over 23 years of oncology drug discovery and development experience.

Most recently, he was Global Head of Oncology Drug Discovery at Janssen (a Johnson & Johnson company). Prior to that, he was Vice President of Oncology and Immunology Drug Discovery at Bristol-Myers Squibb from 1995 to 2010, where he oversaw the company's Princeton, New Jersey research site, including more than 250 scientists and 40 preclinical programs. Earlier in his career, Dr. Kramer served for five years as assistant professor in the Department of Radiation Therapy at Harvard Medical School, and he conducted his postdoctoral work at the National Institutes of Health.

Dr. Kramer is an accomplished scientist and researcher. He earned his Ph.D. in pharmacology at the University of Vermont and holds a B.S. in biology from SUNY at Stonybrook.

Robert P. McKenzie
Executive Vice President of Business Development

Bob McKenzie brings more than 25 years of experience in worldwide business development, as well as general and operational management expertise in sales and marketing, primarily in the technology industry.

Most recently, he was vice president at Amdocs, a global leader in outsourced business services, where he oversaw key global accounts in the company's Broadband, Cable and Satellite division, and was responsible for strategic planning in the cable and satellite industry, product development, business development and program delivery.

Mr. McKenzie is an internationally recognized business development professional, having orchestrated billion-dollar, transnational deals within the telecom and media industries.
He earned his B.A. in business economics from the University of California at Santa Barbara and serves on the board of Stanford Youth Solutions.

George Prendergast, Ph.D.

Dr. Prendergast is an accomplished cancer researcher with experience in the pharmaceutical industry as well as in academia, recognized for his expertise in cancer biology, signal transduction and molecular therapeutics.

Throughout his career, he has become known as an innovator who has the ability to translate basic research findings toward clinical application, most recently in developing a novel drug-like therapy to improve the immune response against a cancer.

He currently is president and CEO of the Lankenau Institute for Medical Research and a professor in the Department of Pathology, Anatomy & Cell Biology, Jefferson Medical School, Thomas Jefferson University. He also is co-director of the Program in Cell Biology & Signaling, KCC, Thomas Jefferson University.

Dr. Prendergast has contributed articles to numerous publications in the field of cancer research and is inventor or co-inventor on a number of published or pending patents.

Carving a New Space

Learn about how our SnAP technology creates a unique binding site within the Fab region that adds functionality to monoclonal antibodies.

» Learn More